SCHEMBL5428002

SCHEMBL5428002

Nc1ccc(S(=O)(=O)C2CCN(C(=O)O)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.44
CA1 P00915 4/20 0.44
CA2 P00918 4/20 0.44
CA7 P43166 4/20 0.44
CA9 Q16790 4/20 0.44
CA14 Q9ULX7 4/20 0.44
SPR P35270 1/20 0.44
HTR2A P28223 7/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
NT5E P21589 1/20 0.43
KCNH2 Q12809 5/20 0.41
HTR2C P28335 4/20 0.41
EPHX2 P34913 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HTR6 P50406 1/20 0.39
MMP2 P08253 1/20 0.39
LMNA P02545 1/20 0.39
DRD2 P14416 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771117 0.86 SPR (0.48) SPRHTR2AKCNH2HTR2CEPHX2
SCHEMBL27917812 0.85 HTR2A (0.58) SPRHTR2AALDH1A1KCNH2HTR2C
SCHEMBL2928335 0.84 ELOVL6 (0.45) SPRHTR2AALDH1A1KCNH2HTR2C
SCHEMBL2931624 0.84 SPR (0.53) CA12CA1CA2CA7CA9
SCHEMBL2634144 0.84 SPR (0.44) CA12CA1CA2CA7CA9
SCHEMBL4106774 0.84 HTR2A (0.56) CA12CA1CA2CA7CA9
SCHEMBL14501554 0.84 CA12 (0.41) CA12CA1CA2CA7CA9
SCHEMBL14501822 0.81 NAMPT (0.43) CA12CA1CA2CA7CA9
SCHEMBL4771067 0.81 MMP13 (0.52) CA12CA1CA2CA7CA9
SCHEMBL16632052 0.81 HTR2A (0.49) SPRHTR2AKCNH2HTR2CEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161645-A1 Thiazole inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161645-A1 Thiazole inhibitors targeting resistant kinase mutations JAK2, ABL1, FLT3 CA12 4829/4885CA1 4859/4885CA2 3797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.